Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy.
Saved in:
| Title: | Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy. |
|---|---|
| Authors: | Day JW; Department of Neurology, Stanford University Medical Center, Stanford, CA, USA., Mendell JR; Center for Gene Therapy, Nationwide Children's Hospital, Columbus, OH, USA.; Department of Pediatrics and Department of Neurology, The Ohio State University, Columbus, OH, USA., Burghes AHM; Department of Neurology and Department of Biological Chemistry and Pharmacology, The Ohio State University, Columbus, OH, USA., van Olden RW; Novartis Gene Therapies Switzerland GmbH, Rotkreuz, Switzerland., Adhikary RR; CONEXTS-Real World Evidence, Novartis Healthcare Private Limited, Hyderabad, India., Dilly KW; Novartis Gene Therapies, Inc., Bannockburn, IL, USA. |
| Source: | Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2023 Sep 20; Vol. 31, pp. 101117. Date of Electronic Publication: 2023 Sep 20 (Print Publication: 2023). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Cell Press Country of Publication: United States NLM ID: 101624857 Publication Model: eCollection Cited Medium: Print ISSN: 2329-0501 (Print) Linking ISSN: 23290501 NLM ISO Abbreviation: Mol Ther Methods Clin Dev Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2329-0501 |
|---|---|
| DOI: | 10.1016/j.omtm.2023.101117 |
